Compare Adaptive Biotechnologies Corp (ADPT) vs Williams Companies Inc (WMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Williams Companies Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Williams Companies Inc trades at $74.77 (market cap $91.82B). The key difference: Williams Companies Inc is far larger — about 27.6× Adaptive Biotechnologies Corp's market cap, and Williams Companies Inc pays a 2.8% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | WMB | |
|---|---|---|
Market Cap | $3.33B | $91.82B |
Sector | Health | Energy |
52-Week High | $22.37 | $79.40 |
52-Week Low | $10.24 | $56.51 |
Enterprise Value | $3.19B | $121.21B |
Dividend Yield | — | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Williams Companies (WMB) trades at $75.08, up 2.65% on the day, approaching its 52-week high of $80.08. The stock shows strong profitability with a 23.4% net income margin and 21.95% ROE, though valuation ratios like P/E of 31.94 appear elevated. Recent news highlights a potential $5.5 billion acquisition of Momentum Midstream to expand natural gas infrastructure, while technical indicators signal a bearish trend despite neutral oscillators.
WMB presents a mixed outlook: robust cash flow growth and a 79% analyst buy rating support upside to the $86.55 consensus target, but high debt levels and recent earnings misses pose risks. The stock's current price near resistance at $75 suggests near-term consolidation, with long-term growth hinging on successful integration of acquisitions and stable energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
